CD274 and neoplasm: Pre-existing biomarkers for ICI outcome, including those used in clinical practice such as PDL1 immunohistochemistry (IHC), tumor mutational burden, or a variety of gene-signatures, are limited in their predictive power (AUC ≈ 0.6–0.75) and require, often inaccessible, tissue biopsies to profile.4